DENTSPLY SIRONA (DY2) Q2 2026 Earnings Report

The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.

The company maintained its 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50 (explicitly excluding the $44 million tariff refund and any incremental tariff impacts), while noting Q3 revenue should decline sequentially due to seasonality and Q3 earnings are expected below Q2 2026 levels excluding the $0.17 per‑share tariff refund benefit; Q2 results included $898 million of revenue (down 4.1% reported, down 6.3% constant currency, and down 3.6% CC after adjusting for Byte and a planned ~$8 million dealer inventory reduction), adjusted EPS of $0.52 (flat year‑over‑year), roughly flat adjusted EBITDA margins, operating cash flow of $99 million versus $48 million prior year, a $44 million tariff refund (≈$0.17/share) that enabled opportunistic repurchases of 1.3 million shares for ≈$12 million (average price below $10), ending cash of $239 million and net debt/EBITDA of 3.2x, and management said it expects the payoff from investments in sales, clinical education and R&D to become increasingly visible beginning in Q4.